Open | 15.77 |
Previous Close | 16.56 |
Day Range | 14.85 - 16.01 |
52-Week Range | 5.12 - 25.29 |
All-Time High | 765.00 |
Avg. Volume (50-day) | 1,835,267.6 |
EPS (TTM) | -4.10 |
Next Earnings Date | 2025-05-12 (AMC) |
Last Earnings Date | 2025-02-20 |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | Yes |
P/E Ratio | -4.04 |
PEG Ratio | - |
Price to Book | 24.51 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | 233.18 M |
Revenue per Share (TTM) | 2.81 |
Shares Outstanding | 88.740 M |
Share Float (%) | 87.41 M |
% Held by Institutions | 109.22 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 18.95 (-20.90%) |
+/- SMA(50) | 20.43 (-26.63%) |
+/- SMA(200) | 15.73 (-4.70%) |
5-Day Perf. | -23.83% |
1-Month Perf. | -23.91% |
3-Month Perf. | -20.52% |
6-Month Perf. | -1.58% |
YTD Perf. | -13.95% |
1-Year Perf. | +115.68% |
RSI(14) | 28.09 |
ATR(14) | 1.24 |
ADX(14) | 23.39 |
Beta (5Y) | 1.12 |
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
TVTX has triggered the following predefined scans:
P&F Double Bottom Breakdown |
P&F Spread Triple Bottom Breakdown |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.